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ABSTRACT The xeroderma pigmentosum complementa-
tion group A (XP-A) protein, XPA, has recently been expressed
In Escherichia colU In a soluble and fully functional form. An
afiMnit column was prepared by lk the XPA protein to a
solid support. When HeLa cell-free extrat capable of excision
repair was applied to the column, >99.9% of the proteins were
in the flow-through. However, the flow-through fraction lacked
excision activity. The activity was restored by adding the hig
salt (1 M KCI) eluate of the column to the flow-through
action. The XPA protein-bound fraction was tested for
specific proteins by an in vitro complementation assay with a
panel of cell-free extracts from DNA repair-deficient human
and rodent celi lines. The XPA-bound fraction complemented
cell-free extracts of excision repair cross-complementing 1
(ERCC-1), ERCC-4 (XP-F), and XP-A mutants. We conciude
that the XPA damage recognition protein makes a ternary
complex with the ERCC1/ERCC4(XPF) heterodimer with a
potential nuclease function.
Xeroderma pigmentosum (XP) is a hereditary disease char-
acterized by photosensitivity, high incidence of actinic can-
cers, and, in some cases, neurological abnormalities (1). The
biochemical basis of XP is a defect in nucleotide-excision
repair (2, 3). Somatic cell genetics of cell lines from XP
patients (4) and of UV-sensitive rodent cell lines isolated in
the laboratory (5) have identified at least eight genes which
are involved in the incision step ofexcision repair: XPA-XPG
and ERCCI* (6, 7). Excision repair in humans encompasses
two basic processes, damage recognition and dual incisions
on either side of the lesion (8). Of the eight known excision
repair proteins, some must be involved in damage recognition
and priming ofDNA in terms of inducing the proper confor-
mational change for the nuclease subunit(s) to bind and carry
out the incision reactions.
The XPA protein is known to be involved in damage
recognition (9-11), and the gene sequence reveals a zinc finger
which might be important for DNA binding (10, 12). We
recently reported expression ofXPA protein in a soluble form
in a heterologous system and purification of and complemen-
tation with the overexpressed protein (6). The purified protein
binds to DNA but has no other detectable activity. Thus, it
must interact with the other subunits to bring about the
excinuclease (an enzyme which removes DNA lesions in an
oligonucleotide by incising the damaged strand on both sides
of the lesion) function. To identify the subunits which interact
with the XPA protein we made an XPA affinity column,
applied cell-free extract (CFE) to it and tested the unbound and
bound fractions for activity. We found that the bound fraction
contained the ERCC1, ERCC4(XPF), and XPA proteins.
These results, combined with the data suggesting that ERCC1
and ERCC4(XPF) make a tight complex (7) and with the
detection ofXPA-ERCC1 interaction by the yeast two-hybrid
system (13) lead us to conclude that XPA, ERCC1, and
ERCC4(XPF) proteins make a ternary complex which partic-
ipates in both damage recognition and incision activities.
MATERIALS AND METHODS
Materials. The amylose resin was obtained from New
England Biolabs. The Affi-Gel 10 resin was from Bio-Rad.
The protease inhibitors pefabloc, pepstatin A, and leupeptin
were purchased from Boehringer Mannheim. HeLa S3 cells
were from the stock of the Lineberger Comprehensive Can-
cer Center (University of North Carolina). XP mutant cell
lines GM2345B (XP-A), GM2252A (XP-B), GM2248B (XP-
C), and GM2485A (XP-D) were obtained from National
Institute of General Medical Studies Human Mutant Cell
Repository (Coriell Institute, Camden, NJ). CHO mutant cell
lines UV20 (ERCC-1), UV41 (ERCC-4 = XP-F), and UV135
(ERCC-5 = XP-G) were purchased from the American Type
Culture Collection.
CFE and Substrate. Whole CFEs from mammalian cell
lines were prepared by the method of Manley et al. (14) and
stored at -800C until use. The substrate was covalently
closed plasmid DNA containing four thymine dimers and
32P-label at the 11th phosphodiester bond 5' to the thymine
dimers (15, 16). The thymine dimer-containing oligomer used
to make the substrate was a gift of J.-S. Taylor (Washington
University, St. Louis).
Purifiation of Fusion Proteins. The maltose-binding pro-
tein (MBP)-XPA and MBP-ERCC1 fusion proteins were
purified through amylose and heparin-agarose columns from
6-liter cultures of Escherichia coli DR153/pMAL-XPA and
DHSa F' lacIq/pMAL-ERCC1, respectively, as described
previously (6). MBP in the form of a MBP-f-galactosidase a
peptide ((gala) fusion was purified from a 1-liter culture of
DH5a F' lacIq/pMAL-c2 as described (6). Briefly, the peak
fractions from the amylose affinity column were combined
and dialyzed against buffer B [25 mM Hepes-KOH, pH 7.6/1
mM EDTA/10 mM 2-mercaptoethanol/10%o (vol/vol) glyc-
erol] plus 50 mM KCl. The protein was loaded onto a 12-ml
DEAE-Sepharose column preequilibrated with buffer B plus
50 mM KCl at a flow rate of 10 ml/hr. The column was
washed with 60 ml of the same buffer and the bound protein
was eluted with buffer B plus 500 mM KC1. The peak
fractions were pooled, dialyzed against storage buffer (25 mM
Abbreviations: XP, xeroderma pigmentosum; CFE, cell-free extract;
MBP, maltose-binding protein.
*XP complementation groups A, B, etc., are represented as XP-A,
XP-B, etc.; the corresponding genes and proteins are represented
by italic and nonitalic symbols without hyphens. Excision repair
cross-complementing (ERCC) mutants, genes, or proteins are rep-
resented by a similar nomenclature. With the exception of ERCC1
all ERCCs correspond to XP genes and proteins. However, even
though strong evidence exists that ERCC4 is XPF, the gene has not
been cloned yet and thus the formal proof of identity is lacking. As
a consequence, we will refer to the protein as ERCC4(XPF).
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HepesKOH, pH 7.9/100 mM KCI/12 mM MgCl2/2 mM
dithiothreitol/0.5 mM EDTA/16.5% glycerol), frozen in dry
ice/ethanol, and stored at -800C.
Preparation of Affinity Columns. The MBP-XPA and
MBP-Pgala fusion proteins (1.65 mg in 1 ml) were adjusted
to 0.2 M KCl and loaded onto 0.6-ml amylose columns
preequilibrated with buffer B plus 0.2M KCl. After recycling
of the flow-through three times, >90%o of the proteins were
bound to the resin as determined by Bradford assay. The
nonspecifically bound E. coli proteins were removed by
washing the columns with 4.8 ml of buffer B plus 1.0M KCl.
Then the columns were reequilibrated with 4.8 ml of buffer B
plus 0.2 M KCl for affinity chromatography with mammalian
CFEs.
Protein Affinity Chromatography. CFEs from HeLa (3 mg of
protein), UV20 (6.5 mg), orUV41 (6.5 mg) were adjusted to 0.2
M KCl and loaded onto (MBP-XPA)-amylose or (MBP-
fgala)-amylose columns preequilibrated with bufferB plus 0.2
M KCL. The column was washed extensively with the same
buffer and the bound proteins were eluted with buffer B plus
1.0 M KCL. Fractions of 0.2 ml were collected and the protein
was located by Bradford assay. The fractions containing
unbound (0.8 ml) and bound (0.6 ml) proteins were dialyzed
against storage buffer and stored at -80TC. For investigating
direct ERCC1-XPA interaction, the MBP-XPA protein (200
pg) was covalently linked to the Affi-Gel 10 resin as described
by the manufacturer (Bio-Rad) and the column (0.25 ml) was
equilibrated with buffer B plus 0.1 M KCl. Purified MBP-
ERCC1 fusion protein (6.8 ug) was applied to the column and,
after extensive washing with the same buffer, the bound
protein was eluted with buffer B plus 1.0 M KCl. The fractions
were analyzed by SDS/PAGE and silver staining.
Complementation Assay for Excinuclease. The human ex-
cinuclease activity was tested by the excision assay as
described by Huang et al. (15). The reaction mixture (50 pi)
contained 40mM Hepes (pH 7.9), 70 mM KCl, 8 mM MgCl2,
2 mM ATP, 20 uM dNTPs, 1.2 mM dithiothreitol, 0.3 mM
EDTA, 10% glycerol, 5 ug of bovine serum albumin, 5 units
of pyruvate kinase, 50 ,g ofphosphoenolpyruvate, 200 ng of
substrate, 100 pg of CFE, and the indicated amounts of
affinity-purified proteins. The mixture was incubated at 300C
for 90 min and the products were analyzed by electrophoresis
in 10%1 polyacrylamide sequencing gels. The level of repair
was estimated from the intensity ofbands of 27- to 29-nt-long
radiolabeled fragments released by the excinuclease. As a
positive control in the complementation assays, 50 ,g ofeach
of two mutant CFEs was included in the reaction mixture.
Endonuclease Assay. The XPA/ERCC1/ERCC4(XPF)
complex was tested for endonuclease activity by incubating
200 ng of 4X174 replicative form I DNA for 90 min at 300C
in 25 p1 of reaction buffer containing 40 mM Hepes (pH 7.9),
70mM KCl, 8mM MgCl2, 2mM ATP, 1.2mM dithiothreitol,
0.3 mM EDTA, 10% glycerol, 2.5 pg of bovine serum
albumin, and 15 t4 of bound fraction. Where indicated the
DNA was irradiated with 450 Jm-2 of 254-nm UV light. The
reaction products were analyzed by electrophoresis in a 1%
agarose gel.
was not augmented by addition ofthe "bound" fraction to the
unbound protein (lanes 3 and 4). In fact with this control
column the level of "bound" protein was at our detection
limit, indicating that MBP does not bind nonspecifically to
human proteins in the CFE.
In contrast, when a similar experiment was performed with
the MBP-XPA affinity column, the unbound fraction was
greatly depleted of excision activity (Fig. 1, lane 5). Addition
of the bound fraction from the MBP column did not restore
the excision activity (lane 6). However, addition of the
XPA-bound fraction (which by itself had no excinuclease
activity; data not shown) restored excision to a level that we
have typically observed (7) in complementation reactions
(lane 7). In fact, ofthe total of 3 mg ofprotein loaded onto the
column, only about 1-3 pg was bound, indicating that the
XPA protein specifically interacts with one or more excision
proteins and removes them from the CFE.
Specific Binding of XPA Protein to ERCC1 and
ERCC4(XPF) Proteins. To identify the excision repair pro-
teins which were removed from the CFE by the XPA affinity
column, we performed complementation assays with CFEs
from a panel of human and rodent mutant cell lines (Fig. 2).
The XPA-bound fraction from the MBP-XPA affinity column
specifically complemented CFEs from human XP-A and
CHO ERCC-1 and ERCC-4 (XP-F) mutants. Since previous
experiments have indicated that the ERCC4 gene of CHO
cells is the rodent counterpart of the human XPF gene and
that ERCC1 and ERCC4 proteins make a tight complex (7) we
conclude that the XPA protein binds to the ERCC1/
ERCC4(XPF) complex. Unexpectedly, the XPA column
retained the XPA protein, suggesting potential direct XPA-
XPA interaction.
Evidence for Binding of XPA to ERCC1 in the
ERCC1/ERCC4(XPF) Complex. Retention of ERCC1/
ERCC4(XPF) complex could conceivably be through inter-
action ofXPA with ERCC1, ERCC4(XPF), or both subunits.
To differentiate between these possibilities we purified the
ERCC1 protein from an E. coli expression system (6) and
applied it to the (MBP-XPA)-Affi-Gel 10 affinity column,
where the fusion protein was covalently linked to the resin.
The ERCC1 protein specifically bound to the XPA affinity












Fractionation ofHuman Excinuclease byXPA Affinity Chro-
matography. We wished to identify the XP proteins which
bound to the XPA damage recognition subunit. HeLa CFE
capable of excision activity was applied to either an (MBP)-
amylose or an (MBP-XPA)-amylose affinity column and the
bound proteins were eluted with 1 M KCL. The unbound and
bound proteins were tested for excision activity. MBP did not
remove any excision repair protein from the CFE, since the
unbound fraction was as active as the CFE before chroma-
tography on this resin (Fig. 1, lanes 1 and 2) and this activity
Lane M 1 2 3 4 5 6 7
FiG. 1. Depletion of HeLa CFE of excinuclease activity by
affinity chromatography on an MBP-XPA affinity column. The
unbound (U; 50 pg) and bound (B; 10 I4) fractions from MBP-
amylose and (MBP-XPA)-amylose columns were tested individually
or in combinations for excinuclease activity as indicated. H, HeLa
CFE (50 pg) excision activity as a positive control; M, a 30-mer as
a size marker; 27-29, the main excision products of human excinu-
clease (15, 16). The smaller fragments are generated by degradation
of the primary excision products by nonspecific nucleases (16).
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FIG. 2. Complementation of human and rodent mutant cell lines
with the HeLa CFE fraction purified through an MBP-XPA affinity
column. (MBP-XPA)-B, bound fraction (10 pA) of the affinity col-
umn. ERCC-1, -4, and XP-A, -B, etc., CFEs from the corresponding
CHO or human mutant cell lines; M, 30-mer marker; 27-29, the main
excision products.
conditions ERCC1 was not retained by the (MBP)-Affi-Gel 10
affinity column (data not shown). These results suggest that
XPA protein binds to the ERCC1/ERCC4(XPF) complex
through its interaction with ERCC1 protein but do not
eliminate the possibility that XPA interacts with
ERCC4(XPF) directly orwhen the latter protein is in the form
of an ERCC1/ERCC4(XPF) complex.
Lack of Damage-Specific Nuclease Activity in the
XPA/ERCC1/ERCC4(XPF) Complex. The XPA protein (9)
and especially its yeast homolog RAD14 (10) bind preferen-
tially to UV-damaged DNA. Furthermore, the yeast ERCC1
homolog RAD10 (17) and possible ERCC4 homolog RAD1 (7)
make a tight complex with endonuclease activity specific for
single-stranded and negatively supercoiled duplex DNA (18,
19). Therefore, it was conceivable that the XPA/ERCC1/
ERCC4(XPF) complex would be targeted to the damage site
by the XPA and would enable ERCC1/ERCC4(XPF) to act as
a damage-specific endonuclease (10, 20). We tested this pos-
sibility by incubating supercoiled DNA with the bound frac-
tion of the XPA affinity column, which has ERCC-1-, ERCC-
4-, and XP-A-complementing activity. The results are shown
in Fig. 4. Under conditions where the XPA-bound fraction
complemented CFEs from all three mutant cell lines, no
specific nicking of the damaged DNA was observed. These
results suggest that the XPA/ERCC1/ERCC4(XPF) complex
needs the aid of the other XP proteins to carry out damage-













FiG. 3. ERCC1 binds directly to XPA protein. Partially purified
MBP-ERCC1 protein (6.8 ;&g) was applied to an MBP-XPA affinity
column prepared by chemically crosslinking MBP-XPA to the Affi-
Gel 10 resin. Following the low-salt (0.1M KCI) wash, bound protein
was eluted by high salt (1.0 M KCI). Fractions of 250 ;4 were
collected and analyzed by SDS/PAGE and silver staining. L, load
(0.75 jMg); V, void volume; FT, flow-through; W, wash; E, elution.
Numbers at left are molecular size markers in kilodaltons. The
MBP-ERCC1 protein is indicated by an arrow.
Fie. 4. Assay for endonuclease activity of XPA/ERCC1/
ERCC4(XPF) complex. Unirrdiated (-UV) and irradiated (+UV)
*X174 replicative form I DNA (200 ng) was incubated in reaction
buffer alone (lanes 1 and 7) or with 15 id of "bound" fractions of
HeLa CFE applied to a MBP-amylose column (lanes 2 and 8) or of
HeLa, ERCC-1, and ERCC-4 CFEs applied to a (MBP-XPA)-
amylose column (lanes 3-6 and 9-12). Lanes 3, 4, 9, and 10, HeLa
CFE bound fractions (two different batches were applied to lanes 3
and 9 and lanes 4 and 10); lanes 5 and 11, ERCC-1 CFE bound
fractions; lanes 6 and 12, ERCC-4 CFE bound fractions. Following
incubation ofDNA with the "affinity-purified" proteins, the reaction
products were analyzed by electrophoresis in a 1% agarose gel. OC,
open circular DNA; CC, covalently closed superhelical DNA. Con-
trol experiments with unfractionated HeLa CFE caused extensive
nicking of DNA by nonspecific nucleases (21).
DISCUSSION
Human excinuclease is an ATP-dependent multisubunit en-
zyme system which removes damaged bases from DNA by
incising the 21st to 23rd phosphodiester bond 5' and the 5th
phosphodiester bond 3' to the lesion (15, 16). While this
excision mechanism differs from the prokaryotic pattern only
in the distance between the lesion and the 5' incision site (the
8th phosphodiester bond to the lesion in E. coli) the human
system entails 8-10 subunits compared with only 3 subunits
in E. coli. Apparently, in the human excinuclease system
more polypeptides are required to target the subunits with the
nuclease active site to their respective phosphodiester bonds.
Recent work with the yeast homologs of human excision
repair proteins has identified two potential nucleases: the
RAD1/RAD10 complex, which is the yeast counterpart ofthe
ERCC4(XPF)/ERCC1 complex (18, 19) and the RAD2 pro-
tein, which is homologous to XPG (20). The remaini
subunits presumably act as molecular matchmakers (22) for
the nuclease components.
Thus, the finding that the potential nuclease,
ERCC4(XPF)/ERCC1, binds to the damage recognition sub-
unit, XPA, was ofconsiderable interest. This finding, in turn,
raises several issues which must be clarified in order to
understand the molecular mechanism of human excinu-
clease. Some of these issues are addressed below.
Binding of XPA to ERCC1/ERCC4(XPF) Cbmplex. Our
data suggest that XPA interacts with the ERCC1 component
of the heterodimer. Li et al. (13) (preceding paper in this
issue) have found that both in the in vivo two-hybrid system
and in an in vitro transcription/translation system, XPA
interacts with ERCC1 and have narrowed down the interac-
tion site to the amino-terminal halves of the two proteins.
Although these studies by themselves could not eliminate the
possibility of interaction of ERCC1 with XPA via a third
protein, the finding reported in this paper shows binding of
ERCC1 to XPA in the absence of other human proteins.
Thus, we conclude that XPA directly binds ERCC1, which in
turn binds ERCC4(XPF). Furthermore, since the carboxyl-
terminal half of RADi binds to the carboxyl-terminal half of
RAD10 (23, 24) we consider the interaction scheme in Fig. 5
as a likely model for the interaction of these three subunits:
the amino-terminal half of XPA binds to the amino-terminal
halfofERCC1 (13), whose carboxyl-terminal halfbinds tothe
carboxyl-terminal half of ERCC4(XPF).
Stability of the Ternary Complex. It was not surprising to
find that ERCC1 and ERCC4(XPF) copurify because previ-
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FiG. 5. Model for XPA/ERCC1/ERCC4(XPF) complex. The amino-terminal half ofXPA binds to the amino-terminal half of ERCC1 (13).
The interaction between the carboxyl termini of ERCC1 and ERCC4(XPF) is assumed based on the findings with the yeast homologs of these
proteins, RAD10 and RAD1 (24).
ous work strongly suggested that these two subunits make a
tight complex in humans (7), and in the yeast system such a
complex was directly demonstrated with purified subunits
(23, 24). However, interaction of this complex with XPA was
not expected. First, the yeastXPA homolog RAD14 has been
purified (10) and no interaction with the RAD1/RAD10
complex was reported. Second, the XPA protein was purified
from calfthymus free ofotherXP proteins (9, 25). We suspect
that the interaction of ERCC1 with XPA is not as strong as
its interaction with ERCC4(XPF), and as a consequence the
XPA protein becomes separated from the ERCC1/
ERCC4(XPF) complex by the ion-exchange chromatography
employed to purify the XPA protein. This is consistent with
the finding that XPA-CFE is complemented by CFE of
ERCC1 or ERCC4, in contrast to the lack of complementa-
tion between ERCC1 and ERCC4 extracts (7). However, we
do believe that this interaction is specific and functionally
significant because of all ofthe XP proteins only the ERCC1/
ERCC4(XPF) complex (in addition to XPA) was removed by
XPA affinity chromatography.
Rentin of XPA by the XPA Affinity Column. Purified
XPA protein behaves as a protein of40 kDaby gel permeation
chromatography (11, 25), suggesting that the protein does not
form a homodimer or higher oligomeric species. Therefore,
we were surprised to find that the XPA-bound fraction
contained XPA activity in addition to ERCC1/ERCC4(XPF)
activity. A trivial explanation such as release of the MBP-
XPA protein from the amylose resin by high salt can be
eliminated because the unbound fraction was depleted of
XPA activity. There are two possible explanations for the
observed phenomenon. First, XPA might dimerize at the high
concentrations that are provided by the column. Alterna-
tively, the ERCC1/ERCC4(XPF) complex, when applied to
the affinity column, alternates between complexes formed
with XPA in the CFE and XPA in the resin, resulting in
retardation of the HeLa XPA protein and its coelution with
ERCC1/ERCC4(XPF) complex. Additional experiments are
needed to differentiate between these two possibilities as well
as to eliminate other, less likely mechanisms.
Lack ofEndonuclem Activity in the Ternary Complex. The
yeastRAD1/RAD10 complex degrades single-stranded DNA
endonucleolytically (18, 19) and nicks negatively supercoiled
DNA apparently by attacking the single stranded regions
induced by the negative superhelical turns (19). We failed to
detect such an activity with the affinity-purified XPA/
ERCC1/ERCC4(XPF) complex. The following are possible
explanations. First, the concentration of the complex might
be too low to detect an endonuclease activity at levels
comparable to that seen with the relatively high concentra-
tions ofRAD1/RAD10 complex used in the purified system.
Second, the XPA protein in the ternary complex might
suppress the nonspecific endonuclease of the nonphysiolog-
ical ERCC1/ERCC4(XPF) complex and convert it into a
damage-specific endonuclease. However, such a damage-
specific activity was not observed under our assay condi-
tions. Furthermore, since under these conditions the affinity-
purified ternary complex complemented CFEs from all three
mutant cell lines, we conclude that the lack of specific nicking
of damaged DNA is due to the fact that in humans specific
nicking requires more than these three subunits.
Purcation of ERCC1/ERCC4(XPF) Complex by Affinity
Chromatography. To define the functions of the individual
subunits of human excinuclease it might be necessary to
purify all of the subunits and reconstitute the enzyme in a
defined system. The ERCCI gene has been cloned (17) and
the protein has been expressed in and purified from E. coli in
a functional form (6). Similarly, the XPA protein has been
expressed in E. coli (6, 11, 26), and mutant CFE has been
complemented with the protein made in E. coli. In contrast,
a cDNA clone of XPF is not available yet. Therefore, the
affinity chromatography system described here offers an
alternative method to purify this protein in its functionally
relevant complex form. Indeed, a simple calculation taking
into account that of the 3 mg of HeLa CFE applied to the
column only about 1-3 ug was bound and that the bound
fraction contained essentially all of the ERCC1/
ERCC4(XPF) activity reveals that a >1000-fold purification
is achieved in a single step. One to two additional purification
steps after preparative-scale affinity chromatography should
yield pure protein that can be used in further physical and
biochemical characterization.
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